优化单克隆抗体药物开发用于炎症性肠道疾病
Michael Colwill1,2, Sailish Honap1,3, Silvio Danese4
1Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK.
两种特异性抗体和先进配方等新策略旨在克服炎症性肠病 (IBD) 目前单克隆抗体 (mAb) 治疗的局限性,改善患者的治疗结果.
科学领域:
- 免疫学和胃肠道学
- 生物药物和治疗药物
背景情况:
- 单克隆抗体 (mAb) 疗法已在治疗炎症性肠病 (IBD) 中取得成功.
- 治疗上限仍然存在,限制了目前对IBD的mAb治疗的有效性.
- 需要先进的生物策略来改善IBD管理.
研究的目的:
- 审查新兴的策略,以提高基于mAb的治疗在IBD的疗效.
- 探索超越当前单一向的mAb疗法的新方法.
- 确定通往IBD下一代生物药物的途径.
主要方法:
- 对双细胞因子阻断的双特异抗体的文献综述.
- 对多个mAbs. 的共同配方方法的检查.
- 讨论药物动力学优化技术 (例如,Fc修饰,PEGylation,糖基工程).
主要成果:
- 双特异性抗体提供双重阻断炎症通路,具有潜在的协同效应.
- 联合配方可以扩大免疫覆盖范围并简化分娩.
- 药物动力学优化策略旨在降低免疫性并延长抗体半衰期.
结论:
- 新兴的策略,如双特异性抗体,共同配方和药物动力学优化,对下一代IBD生物药物显示出希望.
- 这些进展有可能克服目前对IBD的mAb治疗的局限性.
- 在这些领域的进一步发展可以显著提高治疗疗效和IBD患者的治疗结果.
更多相关视频
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
